Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
IOVA Iovance Biotherapeutics
6.840
+0.430+6.71%
Post Mkt Price
7.690
+0.850+12.43%
Symbol
IOVA
Company Name
Iovance Biotherapeutics
Listing Date
02/26/2015
Establishment Date
2007
CEO
Mr. Frederick G. Vogt, J.D.,PhD
Market
NASDAQ
Employees
319
Securities Type
DR
Fiscal Year Ends
12-31
Address
825 Industrial Road,Suite 400,4th Floor
City
San Carlos
Province
California
Country
United States of America
Zip code
94070
Phone
1-650-260-7120
Profile
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
Company Overview
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
CEO: Mr. Frederick G. Vogt, J.D.,PhD
Market: NASDAQ
Listing Date: 02/26/2015
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist